Story · Medicine & Biotech
ACAAI: Considerable delay seen from Rx to approval for children's biologics
1 outlet · first reported by Medical Xpress on
There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and… (Medical Xpress)
Coverage, in order
-
ACAAI: Considerable delay seen from Rx to approval for children's biologicsThere is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.